Michael Palmer

9.6k citations

105 papers · 4.8k indexed · 1 hit paper · h-index 36

Impact in

Cancer Research top 1%
- Breast Cancer Treatment Studies
Oncology top 1%
- HER2/EGFR in Cancer Research
- Cancer survivorship and care
- Cancer Risks and Factors
- Bone health and treatments

Papers in

Oncology 28
- Cancer survivorship and care 7
Cancer Research 14
- Breast Cancer Treatment Studies 11

Co-authors: Joseph L. Pater Dongsheng Tu Lois E. Shepherd James N. Ingle Kathleen I. Pritchard Silvana Martino Nicholas J. Robert Edith A. Perez
Journals: Journal of Clinical Oncology (15 papers)Journal of Medicinal Chemistry (7 papers)Annals of Oncology (5 papers)JNCI Journal of the National Cancer Institute (4 papers)Bioorganic & Medicinal Chemistry Letters (4 papers)
Partner nations: United Kingdom Canada United States

In The Last Decade

Michael Palmer

99 papers receiving 4.6k citations

Hit Papers

align trajectories log scale

Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17 2005 · 818 citations

Peers

Countries citing papers authored by Michael Palmer

Since Specialization

Citations

This map shows the geographic impact of Michael Palmer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael Palmer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael Palmer more than expected).

Fields of papers citing papers by Michael Palmer

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael Palmer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael Palmer. The network helps show where Michael Palmer may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Michael Palmer, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael Palmer Line = papers co-authored together Michael Palmer links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Predicted 25-hydroxyvitamin D over the adult lifetime and the risk of ovarian cancer American Journal of Epidemiology ·Jennifer A. Ritonja, Coraline Danieli, 謙二難波, Michael Palmer, 祝彬, Vikki Ho, Michał Abrahamowicz, Anita Koushik	2024	2
2	Robotic-Assisted Surgery Training (RAST): Assessment of Surgeon Console Ergonomic Skills Journal of surgical education ·Maria Castaldi, Michael Palmer, Jorge Con, Roberto Bergamaschi	2023	4
3	1-Methyl-1H-pyrazole-5-carboxamide Derivatives Exhibit Unexpected Acute Mammalian Toxicity Journal of Medicinal Chemistry ·Sarah Preston, José Garcia-Bustos, Moch.Idam Ramdhani, Sheree D. Martin, 황봉취, Abhijit Kundu, 游胜玉, Nghi Nguyen, Yaqing Jiao, Ban‐Feng Ruan, Lian Xue, Fei Huang, Bill C. H. Chang, Sean L. McGee, Timothy N. C. Wells, Michael Palmer, Abdul Jabbar, Robin B. Gasser, Jonathan B. Baell	2020	7
4	Diagnostic accuracy of fungal PCR and β-d-glucan for detection of candidaemia: a preliminary evaluation Journal of Clinical Pathology ·Kong-De-Ling, P. Lewis White, Raquel Posso, Michael Palmer, Elizabeth M. Johnson, Ronan McMullan	2017	15
5	A prospective study of fungal biomarkers to improve management of invasive fungal diseases in a mixed specialty critical care unit Journal of Critical Care ·Alida Fe Talento, Katie Dunne, Martin Moravec, Michael Palmer, Elizabeth M. Johnson, P. Lewis White, Jan Springer, Juergen Loeffler, Thomas Ryan, Daniel Collins, Thomas R. Rogers	2017	23
6	Design, implementation and reporting strategies to reduce the instance and impact of missing patient-reported outcome (PRO) data: a systematic review BMJ Open ·Rebecca Mercieca‐Bebber, Michael Palmer, Michael Brundage, Melanie Calvert, Martin R. Stockler, Madeleine King	2016	85
7	Symptom and Quality of Life Improvement in LUX-Lung 6: An Open-Label Phase III Study of Afatinib Versus Cisplatin/Gemcitabine in Asian Patients With EGFR Mutation-Positive Advanced Non–small-cell Lung Cancer Journal of Thoracic Oncology ·Sarayut Lucien Geater, Chong‐Rui Xu, Caicun Zhou, Chengping Hu, Jifeng Feng, Shun Lü, Yunchao Huang, Wěi Li, Mei Hou, Jian Hua Shi, Kye Young Lee, Michael Palmer, Yang Shi, Juliane Lungershausen, Yi‐Long Wu	2015	49
8	Is progression-free survival associated with a better health-related quality of life in patients with lung cancer? Evidence from two randomised trials with afatinib BMJ Open ·Ingolf Griebsch, Michael Palmer, Peter Fayers, Stuart H. Ellis	2014	16
9	Inhibition of TRPM8 Channels Reduces Pain in the Cold Pressor Test in Humans Journal of Pharmacology and Experimental Therapeutics ·Wendy J. Winchester, Vikram Bhat, Sophie Glatt, Susumu Aoto, Z W Liu, Kelly Conlon, Michael Postlethwaite, Pierre‐Philippe Saintot, Dwi Suryaningtyas, J Gosset, P Vasala, Mark D. Andrews, Paul A. Glossop, Michael Palmer, Deng Liu, Susie M. Collins, Kevin Beaumont, David S. Reynolds	2014	72
10	Extrication time prediction tool Emergency Medicine Journal ·Tim Nutbeam, ІРИНА ЖОВНІР, Андрей Александрович Грецков, J Tynecki, Michael Palmer	2014	11
11	The People’s Republic of China SSRN Electronic Journal ·Chao Xi, Michael Palmer	2011	0
12	1-(2-Ethoxyethyl)-1H-pyrazolo[4,3-d]pyrimidines as potent phosphodiesterase 5 (PDE5) inhibitors Bioorganic & Medicinal Chemistry Letters ·Michael B. Tollefson, William J. Mea, E. Jon Jacobsen, Robert Hughes, John K. Walker, David Fox, Michael Palmer, Sandra K. Freeman, Ying Yu, Brian R. Bond	2010	21
13	The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents Bioorganic & Medicinal Chemistry Letters ·Michael P. DeNinno, Eve Pierer, Andrew Bell, Yue Chen, K. S. Santosh Kumar, S G Kirby, John B. Etienne, Dianna E. Moore, Michael Palmer, Michael Visser, Sylviya Simeonova, William J. Zavadoski, E. Michael Gibbs	2009	32
14	Competing Causes of Death From a Randomized Trial of Extended Adjuvant Endocrine Therapy for Breast Cancer JNCI Journal of the National Cancer Institute ·W V Zober, C. Michael, L. E. Shepherd, Ananda Ruiz Zago Mendes, J. N. Ingle, H. B. Muss, Michael Palmer, Ana Tsalitsatun Nimah, И. Буpиeв	2008	135
15	The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy Annals of Oncology ·Joseph L. Pater, W. Lofters, Benny Zee, E. Dempsey, David Walde, Luana Andrade Lobo, K Wilson, Paul Hoskins, R. Guévin, Savita Verma, Rudolph M. Navari, James E. Krook, John D. Hainsworth, Michael Palmer, Christine Chin	1997	54
16	Nimodipine at a dose that slows ABR latencies does not protect the ear against noise Hearing Research ·James R. Ison, S. Bangaru Priyanga, Michael Palmer, Joseph P. Walton	1997	9
17	Phase III double-blind comparison of dolasetron mesylate and ondansetron and an evaluation of the additive role of dexamethasone in the prevention of acute and delayed nausea and vomiting due to moderately emetogenic chemotherapy. Journal of Clinical Oncology ·W. Lofters, Joseph L. Pater, Benny Zee, E. Dempsey, David Walde, Ludmila Ommundsen, Kenneth S. Wilson, Paul Hoskins, R. Guévin, Savita Verma, Rudolph M. Navari, James E. Krook, John D. Hainsworth, Michael Palmer, Christine Chin	1997	84
18	Ondansetron Compared with Dexamethasone and Metoclopramide as Antiemetics in the Chemotherapy of Breast Cancer with Cyclophosphamide, Methotrexate, and Fluorouracil New England Journal of Medicine ·Martin Levitt, David Warr, Louise Yelle, Mahendra Paudel, David Wolinieck, V. P. SILVA, Kenneth S. Wilson, Jean Latreille, Martin Potvin, Ellen Warner, Kathleen I. Pritchard, Michael Palmer, Benny Zee, Joseph L. Pater	1993	52
19	Controversies in the management of non-small cell lung cancer: the results of an expert surrogate study Radiotherapy and Oncology ·Michael Palmer, Brian O’Sullivan, Robert E. Steele, William J. Mackillop	1990	46
20	2,4-Diamino-6,7-dimethoxyquinoline derivatives as .alpha.1-adrenoceptor antagonists and antihypertensive agents Journal of Medicinal Chemistry ·Simon F. Campbell, 曾妮楠, Michael Palmer	1988	145

About Michael Palmer

Michael Palmer is a scholar working on Oncology, Cancer Research, Small Animals, Gender Studies and Pulmonary and Respiratory Medicine, having authored 105 papers that have together received 4.8k indexed citations. Recurring topics across this work include Estrogen and related hormone effects (15 papers), Breast Cancer Treatment Studies (11 papers), Lung Cancer Treatments and Mutations (10 papers), Advanced Breast Cancer Therapies (7 papers), Cancer survivorship and care (7 papers), Nausea and vomiting management (7 papers), Conflict of Laws and Jurisdiction (6 papers) and Palliative Care and End-of-Life Issues (6 papers). The work is most often cited by research in Cancer Research (1.4k citations), Oncology (2.2k citations), Genetics (1.6k citations), Pulmonary and Respiratory Medicine (1.2k citations) and Orthopedics and Sports Medicine (179 citations). Michael Palmer has collaborated with scholars based in United Kingdom, Canada and United States. Frequent co-authors include Joseph L. Pater, Dongsheng Tu, Lois E. Shepherd, James N. Ingle, Kathleen I. Pritchard, Silvana Martino, Nicholas J. Robert, Edith A. Perez, Hyman B. Muss and Martine Piccart. Their work appears in journals such as Journal of Clinical Oncology, Journal of Medicinal Chemistry, Annals of Oncology, JNCI Journal of the National Cancer Institute and Bioorganic & Medicinal Chemistry Letters.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact